Humana Inc. Q2 2026 Earnings Overview
Humana Inc. (NYSE: HUM) released its second‑quarter 2026 results before the market opened on Wednesday, delivering an adjusted earnings per share (EPS) of $7.61, which exceeded the consensus analyst estimate of $7.23 by $0.38. Revenue for the quarter was $40.89 billion, marginally above the consensus forecast of $40.56 billion.
Despite the earnings beat, the company’s shares declined 8.7% in pre‑market trading following the announcement.
The insurer reaffirmed its full‑year 2026 adjusted EPS guidance at a minimum of $9.00, slightly higher than the analyst consensus of $8.96. However, Humana revised its GAAP EPS outlook downward to a floor of $6.52, down from the prior guidance of at least $8.36.
The Insurance segment reported a GAAP benefit ratio of 91.2%, aligning with management’s expectation of “slightly above 91%.” The company also maintained its full‑year 2026 Insurance segment benefit‑ratio target of 92.75%, with a tolerance of plus or minus 25 basis points.
"The first half of the year went well, and we’re right where we said we’d be at Investor Day last year," said Jim Rechtin, President and Chief Executive Officer. "When we get the clinical care right and run the business more efficiently, everything else follows—stronger earnings and better health and experiences for the people we serve."
Humana confirmed its individual Medicare Advantage membership is expected to grow approximately 25% over the 2025 baseline, driven by new sales and improved retention under its customer‑led benefit strategy and revised customer‑service approach.
Year‑to‑date, the company added 130,900 patients, representing a 27% increase in its CenterWell Senior Primary Care network.
In a strategic expansion, Humana secured a statewide Illinois Medicaid managed‑care contract that is slated to become operational in January 2027. Humana was the sole new entrant awarded the contract, joining five incumbent providers.
---